Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence (SURE)

0
81

Opportunity ID: 330722
Opportunity Number: NOT-GM-21-003
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence (SURE)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.859
Eligible Applicants: Public and State controlled institutions of higher education
Private institutions of higher education
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Jan 05, 2021
Last Updated Date: Jan 05, 2021
Estimated Synopsis Post Date: Mar 20, 2021
Fiscal Year: 2022
Award Ceiling: $100,000
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The National Institute of General Medical Sciences intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for research as part of the Support for Research Excellence (SuRE) Program. SuRE Program is replacing the SCORE Program. Two distinct funding opportunity announcements will be used to support research projects led by faculty investigators at different career stages. A third SuRE funding opportunity announcement will support a national resource center to provide infrastructure development to SuRE-eligible institutions and application services to faculty investigators. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in early Spring 2021 with an expected application due date in late Spring 2021. Details of the planned FOA are provided below.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence (SURE)

LEAVE A REPLY

Please enter your comment!
Please enter your name here